The results of the use of immune checkpoint inhibitors (ICI) pembrolizumab and nivolumab in the first line treatment of patients with metastatic gastric cancer. The experience of the oncological service of Moscow ; Результаты применения ингибиторов контрольных точек иммунного ответа (ИКТ) пембролизумаба и ниволумаба у больных метастатическим раком желудка в I линии. Опыт онкологической службы г. Москвы

Συγγραφείς: N. N. Semenov, M. Yu. Fedyanin, L. G. Zhukova, I. E. Khatkov, D. L. Stroyakovskii, I. A. Pokataev, Н. Н. Семёнов, М. Ю. Федянин, Л. Г. Жукова, И. Е. Хатьков, Д. Л. Строяковский, И. А. Покатаев

Πηγή: Malignant tumours; Том 15, № 1 (2025); 27–35 ; Злокачественные опухоли; Том 15, № 1 (2025); 27–35 ; 2587-6813 ; 2224-5057

Θεματικοί όροι: химиотерапия, immune checkpoint inhibitors, chemotherapy, ингибиторы контрольных точек иммунитета

Περιγραφή αρχείου: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/1446/1033; Kang Y.K., Kang W.K., Shin D.B., et al. Capecitabine / cisplatin versus 5‑fluorouracil / cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol 2009;20(4):666–73. https://doi.org/10.1093/annonc/mdn717; Al-Batran S.E., Hartmann J.T., Probst S., et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 2008;26(9):1435–42. https://doi.org/10.1200/JCO.2007.13.9378; Van Cutsem E., Moiseyenko V.M., Tjulandin S.A., et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006;24(31):4991–7. https://doi.org/10.1200/JCO.2006.06.8429; Al-Batran S.E., Hartmann J.T., Hofheinz R., et al. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol 2008;19(11):1882–7. https://doi.org/10.1093/annonc/mdn403; Pietrantonio F., Randon G., Lonardi S., et al. Ramucirumab plus paclitaxel as switch maintenance versus continuation of oxaliplatin-based chemotherapy in patients (pts) with advanced HER2‑negative gastric or gastroesophageal junction (GEJ) cancer: The ARMANI phase III trial. J Clin Oncol 2024; suppl 17 (abstr LBA4002). https://doi.org/10.1200/JCO.2024.42.17_suppl.LBA4002; Bang Y.J., Van Cutsem E., Feyerislova A., et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2‑positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376(9742):687–697. https://doi.org/10.1016/S0140-6736(10)61121-X; Muro K., Chung H.C., Shankaran V., et al. Pembrolizumab for patients with PD-L1‑positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol 2016;17(6):717–726. https://doi.org/10.1016/S1470-2045(16)00175-3; Janjigian Y.Y., Bendell J., E. Calvo, et al. CheckMate-032 study: efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer. J Clin Oncol 2018;36(28):2836–2844. https://doi.org/10.1200/JCO.2017.76.6212; Janjigian Y.Y., Shitara K., Moehler M., et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 2021;398(10294):27–40. https://doi.org/10.1016/S0140-6736(21)00797-2; Rha S.Y., Wyrwicz L., Weber P.E.Y., et al. KEYNOTE-859 study of pembrolizumab plus chemotherapy for advanced HER2‑negative gastric or gastroesophageal junction (G / GEJ) cancer: Outcomes in the protocol-specified PD-L1-selected populations. J Clin Oncol 2023;41 (suppl 16; abstr 4014); Chao J., Fuchs C.S., Shitara K., et al. Assessment of pembrolizumab therapy for the treatment of microsatellite instability-high gastric or gastroesophageal junction cancer among patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 clinical trials. JAMA Oncol 2021;7(6):895–902. https://doi.org/10.1001/jamaoncol.2021.0275; Janjigian Y.Y., Ajani J.A., Moehler M., et al. First-Line nivolumab plus chemotherapy for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 3‑year follow-up of the phase III CheckMate 649 trial. J Clin Oncol 2024;42(17):2012–2020. https://doi.org/10.1200/JCO.23.01601; https://www.malignanttumors.org/jour/article/view/1446

Διαθεσιμότητα: https://www.malignanttumors.org/jour/article/view/1446
https://doi.org/10.18027/2224-5057-2025-039

Cardiovascular complications of immune checkpoint inhibitors

Συγγραφείς: A. A. Kulievа, E. I. Emelina, G. E. Gendlin, I. G. Nikitin, S. K. Zyryanov, S. I. Varentsov, I. I. Zakharova

Πηγή: Качественная клиническая практика, Vol 0, Iss 4, Pp 55-65 (2020)

Θεματικοί όροι: кардиотоксичность, ингибиторы контрольных точек иммунитета, миокардит, кардиоонкология, Medical technology, R855-855.5, Pharmacy and materia medica, RS1-441

Περιγραφή αρχείου: electronic resource

Relation: https://www.clinvest.ru/jour/article/view/477; https://doaj.org/toc/2588-0519; https://doaj.org/toc/2618-8473

Σύνδεσμος πρόσβασης: https://doaj.org/article/23ade83b8eca4366b741089ccfd48653

Modern strategies for the treatment of patients with kidney cancer of brain metastases: literature review ; Современные стратегии лечения пациентов с метастазами рака почки в головной мозг: обзор литературы

Συγγραφείς: K. E. Roshchina, A. Kh. Bekyashev, D. R. Naskhletashvili, I. K. Osinov, A. N. Savateev, D. A. Khalafyan, К. Е. Рощина, А. Х. Бекяшев, Д. Р. Насхлеташвили, И. К. Осинов, А. Н. Саватеев, Д. А. Халафян

Πηγή: Head and Neck Tumors (HNT); Том 12, № 1 (2022); 107-113 ; Опухоли головы и шеи; Том 12, № 1 (2022); 107-113 ; 2411-4634 ; 2222-1468 ; 10.17650/2222-1468-2022-12-1

Θεματικοί όροι: ингибиторы контрольных точек иммунитета, brain metastases, local treatment, targeted therapy, immune checkpoint inhibitors, метастазы в головной мозг, локальное лечение, таргетная терапия

Περιγραφή αρχείου: application/pdf

Relation: https://ogsh.abvpress.ru/jour/article/view/742/520; Schouten L., Rutten J., Huveneers H. et al. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 2002;94(10): 2698–705. DOI:10.1002/cncr.10541.; Sun M., Velasco G., Brastianos P., Aizer A. et al. The development of brain metastases in patients with renal cell carcinoma: epidemiologic trends, survival, and clinical risk factors using a population-based cohort. Eur Urol Focus 2019;5(3):474–81. DOI:10.1016/j.euf.2017.12.007.; Голанов А.В., Банов С.М., Ильялов С.Р. и др. Современные подходы к лучевому лечению метастатического поражения головного мозга. Злокачественные опухоли 2014;3:137–40. DOI:10.18027/2224-5057-2014-3-137-140.; Heng D., Choueiri T., Rini B. et al. Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials. Ann Oncol 2014;25(1):149–54. DOI:10.1093/annonc/mdt492.; Bianchi M., Sun M., Jeldres C. et al. Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. Ann Oncol 2012;23(4):973–80. DOI:10.1093/annonc/mdr362.; Sun M., Velasco D.G., Brastianos P. et al. The development of brain metastases in patients with renal cell carcinoma: epidemiologic trends, survival, and clinical risk factors using a populationbased cohort. Eur Urol Focus 2019;5(3):474–81. DOI:10.1016/j.euf.2017.12.007.; Zhuang W., Li Y., Chen P. et al. Do renal cell carcinoma patients with brain metastases still need nephrectomy? Int Urol Nephrol 2019;51(6):941–9. DOI:10.1007/s11255-019-02139-9.; Ke Z., Chen S., Chen Y. et al. Risk factors for brain metastases in patients with renal cell carcinoma. BioMed Res Int 2020;2020:6836234. DOI:10.1155/2020/6836234.; Tsivian M., Moreira D., Caso Jorge R. et al. Cigarette smoking is associated with advanced renal cell carcinoma. J Clin Oncol 2011;29(15):2027–31. DOI:10.1200/JCO.2010.30.9484.; Ljungberg B., Albiges L., Abu-Ghanem Y. et al. European Association of Urology Guidelines on Renal Cell Carcinoma: the 2019 update. Eur Urol 2019;75(5):799–810. DOI:10.1016/j.eururo.2019.02.011.; Ward R., Tanaka H., Campbell S. et al. 2017 AUA renal mass and localized renal cancer guidelines: imaging implications. Radio Graphics 2018;38(7):2021–33. DOI:10.1148/rg.2018180127.; Sperduto P., Kased N., Roberge D. et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 2012;30(4):419–25. DOI:10.1200/JCO.2011.38.0527.; Gaspar L., Scott C., Rotman M. et al. Recursive partitioning analysis (RPA) of prognostic factors in three radiation therapy oncology group (RTOG) brain metastases trials. Int J Radiation Oncol Biol Phys 1997;37(4):745–51. DOI:10.1016/s0360-3016(96)00619-0.; Алешин В.А., Бекяшев А.Х., Белов Д.М. и др. Индивидуализация лечения пациентов с церебральными метастазами злокачественных опухолей. Прогностическая шкала TuNS. Злокачественные опухоли 2017;7(4):48–52. DOI:10.18027/2224-5057-2017-7-4-48-52.; Ali M., Hirshman B., Wilson B. et al. Improving the prognostic value of diseasespecific graded prognostic assessment model for renal cell carcinoma by incorporation of cumulative intracranial tumor volume. World Neurosurg 2017;108:151–6. DOI:10.1016/j.wneu.2017.07.109.; Ali Z., Rottey S., Barthelemy P. et al. Brain metastasis and renal cell carcinoma: prognostic scores assessment in the era of targeted therapies. Anticancer Res 2019;39(6):2993–3002. DOI:10.21873/anticanres.13431.; Vickers M., Al-Harbi H., Choueiri T. et al. Prognostic factors of survival for patients with metastatic renal cell carcinoma with brain metastases treated with targeted therapy: results from the international metastatic renal cell carcinoma database consortium. Clin Genitourin Cancer 2013;11(3):311–5. DOI:10.1016/j.clgc.2013.04.012.; Банов С.М., Голанов А.В., Ильялов С.Р. и др. Результаты радиохирургического и лекарственного лечения пациентов с метастазами в головной мозг. Опухоли головы и шеи 2017;7(3):19–30. DOI:10.17650/2222-14682017-7-3-19-30.; Noordijk E., Vecht С., Haaxma-rekhe H. et al. The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age. Int J Radiat Oncol Biol Phys 1994;29(4):711–6. DOI:10.1016/0360-3016(94)90558-4.; Ветлова Е.Р., Банов С.М., Голанов А.В. Современная стратегия комбинации хирургического и лучевого лечения у пациентов с метастазами в головном мозге. Журнал «Вопросы нейрохирургии» им. акад. Н.Н. Бурденко 2017;81(6):108–15. DOI:10.17116/neiro2017816108-115.; Hara W., Tran P., Li G. et al. Cyberknife for brain metastases of malignant melanoma and renal cell carcinoma. Neurosurgery 2009;64 (2 Suppl):A26–32. DOI:10.1227/01.NEU.0000339118.55334.EA.; Sheehan J., Sun M., Kondziolka D. et al. Radiosurgery in patients with renal cell carcinoma metastasis to the brain: longterm outcomes and prognostic factors influencing survival and local tumor control. J Neurosurg 2003;98(2):342–9. DOI:10.3171/jns.2003.98.2.0342.; Soltys S., Adler J., Lipani J. et al. Stereotactic radiosurgery of the postoperative resection cavity for brain metastases. Int J Radiat Oncol Biol Phys 2008;70(1):187–93. DOI:10.1016/j.ijrobp.2007.06.068.; Chang E., Selek U., Hassenbusch S. et al. Outcome variation among “radioresistant” brain metastases treated with stereotactic radiosurgery. Neurosurgery 2005;56(5):936–45. DOI:10.1227/01.NEU.0000158324.20757.AC.; Verma J., Jonasch E., Allen P. et al. The impact of tyrosine kinase inhibitors on the multimodality treatment of brain metastases from renal cell carcinoma. Am J Clin Oncol 2013;36(6):620–4. DOI:10.1097/COC.0b013e31825d59db.; Ippen F., Mahadevan A., Wong E. et al. Stereotactic radiosurgery for renal cancer brain metastasis: prognostic factors and the role of whole-brain radiation and surgical resection. J Oncol 2015;2015:636918. DOI:10.1155/2015/636918.; Бекяшев А.Х., Голанов А.В., Древаль О.Н. и др. Рак почки с метастазами в головной мозг. Факторы прогноза и результаты лечения. Опухоли головы и шеи 2016;6(3):53–60. DOI:10.17650/2222-1468-2016-6-353-60.; Molenaar R., Wiggenraad R., Kanter A. et al. Relationship between volume, dose and local control in stereotactic radiosurgery of brain metastasis. Br J Neurosurg 2009;23(2):170–8. DOI:10.1080/02688690902755613.; Vogelbaum M., Angelov L., Lee S. et al. Local control of brain metastases by stereotactic radiosurgery in relation to dose to the tumor margin. J Neurosurg 2006:104(6):907–12. DOI:10.3171/jns.2006.104.6.907.; Yamamoto M., Kawabe T., Sato Y. et al. Stereotactic radiosurgery for patients with multiple brain metastases: a casematched study comparing treatment results for patients with 2–9 versus 10 or more tumors. J Neurosurg 2014;121:16–25. DOI:10.3171/2014.8.GKS141421.; Dirk R., Stefan H., Volker R. Radiosurgery with 20 Gy provides better local contol of 1-3 brain metastases from breast cancer than with lower doses. Anticancer Res 2015;35(1):333–6.; Алешин В.А., Карахан В.Б., Бекяшев А.Х., Белов Д.М. Метастазы рака легкого в головной мозг – роль нейрохирургического этапа лечения. Опухоли головы и шеи 2016;6(2):42–9. DOI:10.17650/2222-14682016-6-2-42-49.; Белов Д.М., Карахан В.Б., Бекяшев А.Х., Алешин В.А. Хирургический этап в комплексном лечении пациенток с церебральными метастазами рака молочной железы. Злокачественные опухоли 2014;3:110–5. DOI:10.18027/2224-5057-2014-3110-115.; Soffietti R., Ahluwalia M., Lin N. et al. Management of brain metastases according to molecular subtypes. Nat Rev Neurol 2020;16(10):557–74. DOI:10.1038/s41582-020-0391-x.; Pardridge W. Drug and gene delivery to the brain. Neuron 2002;36(4):555–8. DOI:10.1016/s0896-6273(02)01054-1.; Hu S., Chen Z., Franke R., Orwick S. et al. Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin Cancer Res 2009;15(19):6062–9. DOI:10.1158/1078-0432.CCR09-0048.; Beck J., Procopio G., Bajetta E. et al. Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse. Ann Oncol 2011;22(8):1812–23. DOI:10.1093/annonc/mdq651.; Henderson C., Bukowski R., Stadler W. et al. The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: subset analysis of patients (pts) with brain metastases (BM). J Clin Oncol 2007;25(18_suppl.):15506. DOI:10.1200/jco.2007.25.18_suppl.15506.; Jäger D., Ma J., Mardiak J. et al. Sorafenib treatment of advanced renal cell carcinoma patients in daily practice: the large international PREDICT study. Clin Genitourin Cancer 2015;13(2):156– 64.е1. DOI:10.1016/j.clgc.2014.07.007.; Gore M., Hariharan S., Porta C. et al. Sunitinib in metastatic renal cell carcinoma patients with brain metastases. Cancer 2011;117(3):501–9. DOI:10.1002/cncr.25452.; Sternberg C., Calabrò F., Bracarda S. et al. Safety and efficacy of sunitinib in patients from Italy with metastatic renal cell carcinoma: final results from an expandedaccess trial. Oncology 2015;88(5):273–80. DOI:10.1159/000369256.; Jacobs C., Kim D., Straka C. et al. Prolonged survival of a patient with papillary renal cell carcinoma and brain metastases using pazopanib. J Clin Oncol 2013;31(7):e114–7. DOI:10.1200/JCO.2012.46.0501.; Matrana M., Duran C., Shetty A. et al. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies. Eur J Cancer 2013;49(15):3169–75. DOI:10.1016/j.ejca.2013.06.003.; Матвеев В.Б., Ольшанская А.С., Волкова М.И. Кабозантиниб: от исследований к реальной клинической практике. Онкоурология 2019;15(3):28–41. DOI:10.17650/1726-97762019-15-3-28-41.; Négrier S., Moriceau G., Attignon V. et al. Activity of cabozantinib in radioresistant brain metastases from renal cell carcinoma: two case reports. J Med Case Rep 2018;12(1):351. DOI:10.1186/s13256-018-1875-9.; Hirsch L., Chanza N., Farah S. et al. Clinical activity and safety of cabozantinib for brain metastases in patients with renal cell carcinoma. JAMA Oncol 2021;7(12):1815–23. DOI:10.1001/jamaoncol.2021.4544.; Hirsch L., Chanza N., Farah S. et al. Activity and safety of cabozantinib (cabo) in brain metastases (BM) from metastatic renal cell carcinoma (mRCC): an international multicenter study. J Clin Oncol 2021;39(6_suppl.):310. DOI:10.1200/JCO.2021.39.6_suppl.310.; Kattan J., Rassy E., Assi T. et al. A comprehensive review of the role of immune checkpoint inhibitors in brain metastasis of renal cell carcinoma origin. Crit Rev Oncol Hematol 2018;130:60–9. DOI:10.1016/j.critrevonc.2018.08.001.; Berghoff A., Venur V., Preusser M., Ahluwaliaeng M. Immune checkpoint inhibitors in brain metastases: from biology to treatment. Am Soc Clin Oncol Educ Book 2016;35:e116–22. DOI:10.1200/EDBK_100005.; Flippot R., Dalban C., Laguerre B. et al. Safety and efficacy of nivolumab in brain metastases from renal cell carcinoma: results of the GETUG-AFU 26 NIVOREN multicenter phase II study. J Clin Oncol 2019;37(23);2008–16. DOI:10.1200/JCO.18.02218.; Emamekhoo H., Olsen M., Carthon B. et al. Safety and efficacy of nivolumab plus ipilimumab (NIVO+IPI) in patients with advanced renal cell carcinoma (aRCC) with brain metastases: interim analysis of CheckMate 920. J Clin Oncol 2019;37(15_suppl.):4517. DOI:10.1002/cncr.34016.; https://ogsh.abvpress.ru/jour/article/view/742

Διαθεσιμότητα: https://ogsh.abvpress.ru/jour/article/view/742
https://doi.org/10.17650/2222-1468-2022-12-1-107-113

A case report of immune-related pneumonitis after combined treatment of non small cell lung cancer ; Клинический случай иммуноопосредованного пневмонита после комбинированного лечения немелкоклеточного рака легкого

Συγγραφείς: E. S. Denisova, M. S. Ardzinba, K. K. Laktionov, D. I. Yudin, K. A. Sarantseva, G. V. Shcherbakova, N. V. Marinichenko, Е. С. Денисова, М. С. Ардзинба, К. К. Лактионов, Д. И. Юдин, К. А. Саранцева, Г. В. Щербакова, Н. В. Мариниченко

Πηγή: Meditsinskiy sovet = Medical Council; № 9 (2020); 258-264 ; Медицинский Совет; № 9 (2020); 258-264 ; 2658-5790 ; 2079-701X

Θεματικοί όροι: иммуноопосредованные нежелательные явления, pneumonitis, Immune checkpoint inhibitors, PD-1, Nivolumab, case report, Immune related adverse events, ингибиторы контрольных точек иммунитета, пневмонит, ниволумаб, клинический случай

Περιγραφή αρχείου: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/5743/5241; Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. doi:10.3322/caac.21590.; Bareschino M.A., Schettino C., Rossi A., Maione P., Sacco P.C., Zeppa R., Gridelli C. Treatment of advanced non small cell lung cancer. J Thorac Dis. 2011;3(2):122–133. doi:10.3978/j.issn.2072-1439.2010.12.08.; Kim E.S., Hirsh V., Mok T., Socinski M.A., Gervais R., Wuet Y.L. et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet. 2008;372(9652):1809– 1818. doi:10.1016/S0140-6736(08)61758-4.; Iacono D., Chiari R., Metro G., Bennati C., Bellezza G., Cenci M. et al. Future options for ALK-positive non-small cell lung cancer. Lung Cancer. 2015;87(3):211–219. doi:10.1016/j.lungcan.2014.12.017.; Asahina H., Sekine I., Horinouchi H., Nokihara H., Yamamoto N., Kubota K. et al. Retrospective analysis of third-line and fourth-line chemotherapy for advanced non-small-cell lung cancer. Clin Lung Cancer. 2012;13(1):39–43. doi:10.1016/j.cllc.2011.06.008.; Stinchcombe T.E. The Use of EGFR Tyrosine Kinase Inhibitors in EGFR Wild-Type Non-Small-Cell Lung Cancer. Curr Treat Options Oncol. 2016;17(4):18. doi:10.1007/s11864-016-0394-4.; Doroshow D.B., Sanmamed M.F., Hastings K., Politi K., Rimm D.L., Chen L. et al. Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes. Clin Cancer Res. 2019;25(15):4592–4602. doi:10.1158/1078-0432.CCR-18-1538.; Brahmer J., Reckamp K.L., Baas P., Crinò L., Eberhardt W.E., Poddubskaya E. et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell NonSmall-Cell Lung Cancer. N Engl J Med. 2015;373(2):123–135. doi:10.1056/NEJMoa1504627.; Borghaei H., Paz-Ares L., Horn L., Spigel D.R., Steins M., Ready N.E. et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015;373(17):1627–1639. doi:10.1056/NEJMoa1507643.; Postow M.A. Managing immune checkpoint-blocking antibody side effects. Am Soc Clin Oncol Educ Book. 2015;76–83. doi:10.14694/EdBook_AM.2015.35.76.; Gandhi L., Rodríguez-Abreu D., Gadgeel S., Esteban E., Felip E., Angelis F.D. et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med. 2018;378(22):2078–2092. doi:10.1056/NEJMoa1801005.; Vokes E.E., Ready N., Felip E., Horn L., Burgio M.A., Antonia S.J. et al. Nivolumab versus docetaxel in previously treated advanced non-smallcell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases. Ann Oncol. 2018;29(4):959–965. doi:10.1093/annonc/mdy041.; Yasuda K., Tanaka T., Ishihara S., Otani K., Nishikawa T., Kiyomatsu T. et al. Intestinal perforation after nivolumab immunotherapy for a malignant melanoma: a case report. Surg Case Rep. 2017;3(1):94. doi:10.1186/s40792-017-0370-7.; Guan M., Zhou Y.P., Sun J.L., Chen S.C. Adverse events of monoclonal antibodies used for cancer therapy. Biomed Res Int. 2015;2015:428169. doi:10.1155/2015/428169.; Weber J.S., Yang J.C., Atkins M.B., Disis M.L. Toxicities of Immunotherapy for the Practitioner. J Clin Oncol. 2015;33(18):2092–2099. doi:10.1200/JCO.2014.60.0379.; Topalian S.L., Hodi F.S., Brahmer J.R., Gettinger S.N., Smith D.C., McDermott D.F. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–2454. doi:10.1056/NEJMoa1200690.; Nishino M., Giobbie-Hurder A., Hatabu H., Ramaiya N.H., Hodi F.S. Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer: A Systematic Review and Meta-analysis. JAMA Oncol. 2016;2(12):1607–1616. doi:10.1001/jamaoncol.2016.2453.; Wang Y., Zhou S., Yang F., Qi X., Wang X., Guan X. et al. Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis. JAMA Oncol. 2019;5(7):1008–1019. doi:10.1001/jamaoncol.2019.0393.; Toh C.K., Wong E.H., Lim W.T., Leong S.S., Fong K.M., Wee J. et al. The impact of smoking status on the behavior and survival outcome of patients with advanced non-small cell lung cancer: a retrospective analysis. Chest. 2004;126(6):1750–1756. doi:10.1378/chest.126.6.1750.; Bouros D., Hatzakis K., Labrakis H., Zeibecoglou K. Association of malignancy with diseases causing interstitial pulmonary changes. Chest. 2002;121(4):1278–1289. doi:10.1378/chest.121.4.1278.; De Velasco G., Je Y., Bossé D., Awad M.M., Ott P.A., Moreira R.B. et al. Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients [published correction appears in Cancer Immunol Res. 2018;6(4):498–499]. Cancer Immunol Res. 2017;5(4):312–318. doi:10.1158/2326-6066.CIR-16-0237.; Naidoo J., Wang X., Woo K.M., Iyriboz T., Halpenny D., Cunningham J. et al. Pneumonitis in Patients Treated With Anti-Programmed Death-1/ Programmed Death Ligand 1 Therapy [published correction appears in J Clin Oncol. 2017;35(22):2590]. J Clin Oncol. 2017;35(7):709–717. doi:10.1200/JCO.2016.68.2005.; Xia L., Liu Y., Wang Y. PD-1/PD-L1 Blockade Therapy in Advanced NonSmall-Cell Lung Cancer: Current Status and Future Directions. Oncologist. 2019;24(1):31–41. doi:10.1634/theoncologist.2019-IO-S1-s05.; Shao J., Wang C., Ren P., Jiang Y., Tian P., Li W. Treatment- and immunerelated adverse events of immune checkpoint inhibitors in advanced lung cancer. Biosci Rep. 2020;40(5):BSR20192347. doi:10.1042/BSR20192347.; Engel-Nitz N.M., Johnson M.P., Bunner S.H., Ryan K.J. Real-World Costs of Adverse Events in First-Line Treatment of Metastatic Non-Small Cell Lung Cancer. J Manag Care Spec Pharm. 2020;26(6):729–740. doi:10.18553/jmcp.2020.26.6.729.

Διαθεσιμότητα: https://www.med-sovet.pro/jour/article/view/5743
https://doi.org/10.21518/2079-701X-2020-9-258-264

Comparison of immunohistochemical tests in the CLOVER study by Russian society of clinical oncology ; Сравнение иммуногистохимических тестов в рамках исследования CLOVER Российского общества клинической онкологии

Συγγραφείς: L. E. Zavalishina, P. E. Povilaitite, N. A. Savelov, Yu. Yu. Andreeva, A. V. Petrov, G. A. Raskin, E. A. Kharitonova, I. M. Pugach, A. A. Rumyantsev, G. A. Frank, E. N. Imyanitov, I. V. Tsimafeyeu, S. A. Tjulandin, Л. Э. Завалишина, П. Э. Повилайтите, Н. А. Савелов, Ю. Ю. Андреева, А. В. Петров, Г. А. Раскин, Е. А. Харитонова, И. М. Пугач, А. А. Румянцев, Г. А. Франк, Е. Н. Имянитов, И. В. Тимофеев, С. А. Тюляндин

Πηγή: Malignant tumours; Том 9, № 4 (2019); 25-31 ; Злокачественные опухоли; Том 9, № 4 (2019); 25-31 ; 2587-6813 ; 2224-5057

Θεματικοί όροι: иммуногистохимический метод, immune checkpoint inhibitors, PD-L1 expression assessment, immunohistochemical method, ингибиторы контрольных точек иммунитета, оценка экспрессии PD-L1

Περιγραφή αρχείου: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/697/478; Rangachari D, Costa DB. From Hope to Reality: Durable Overall Survival With Immune Checkpoint Inhibitors for Advanced Lung Cancer. J Clin Oncol. 2019 Jun 2: JCO1901207. doi:10.1200/JCO/19.01207. [Epub ahead of print].; Garon EB, Hellmann MD, Rizvi NA, Carcereny E, Leighl NB, et al. Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study. J Clin Oncol. 2019 Jun 2: JCO1900934. doi:10.1200/JCO.19.00934. [Epub ahead of print].; Mok TSK, Wu YL, Kudaba I, Kowalski DM, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1 expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, openlabel, controlled, phase 3 trial. Lancet. 2019 May 4;393 (10183):1819 – 1830.; U. S. Food & Drug Administration. FDA approves pembrolizumab in combination with chemotherapy for first-line treatment of metastatic squamous NSCLC. https://www.fda.gov/drugs/fda-approves-pembrolizumab-combinationchemotherapy-first-line-treatment-metastatic-squamous-nsclc Accessed August 12, 2019.; Pai-Scherf L, Blumenthal GM, Li H, Subramaniam S, et al. FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond. Oncologist. 2017 Nov;22 (11):1392 – 1399.; Laktionov K. K., Sarantseva K. A., Breder V. V., Okruzhnova M. A., Peregudova M. V. Immunotherapy for non-small cell lung cancer treatment. Malignant tumours. 2016; (3):17 – 24. (In Russ.).; NCCN Clinical Practice Guidelines in Oncology. Non-small cell lung cancer. Version 5.2019. https://www.nccn.org/professionals /physician_gls /PDF /nscl.pdf; Rittmeyer A, Barlesi F, Waterkamp D, Park K, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017 Jan 21;389 (10066):255 – 265.; Kazandjian D, Suzman DL, Blumenthal G, Mushti S, et al. FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy. Oncologist. 2016 May;21 (5):634 – 42.; Antonia SJ, Villegas A, Daniel D, Vicente D, et al. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017 Nov 16;377 (20):1919 – 1929.; Imyanitov EN, Demidova IA, Gordiev MG, Filipenko ML, et al. Distribution of EGFR Mutations in 10,607 Russian Patients with Lung Cancer. Mol Diagn Ther. 2016 Aug;20 (4):401 – 6.; Zavalishina L, Tsimafeyeu I, Povilaitite P, Raskin G, et al. RUSSCO-RSP comparative study of immunohistochemistry diagnostic assays for PD-L1 expression in urothelial bladder cancer. Virchows Arch. 2018 Dec;473 (6):719 – 724.; Isobe K, Kakimoto A, Mikami T, Kaburaki K, et al. PD-L1 mRNA expression in EGFR-mutant lung adenocarcinoma. Oncol Rep. 2018 Jul;40 (1):331 – 338.; Tsao MS, Kerr KM, Kockx M, Beasley MB, et al. PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project. J Thorac Oncol. 2018 Sep;13 (9):1302 – 1311.; Ratcliffe MJ, Sharpe A, Midha A, Barker C, et al. Agreement between Programmed Cell Death Ligand-1 Diagnostic Assays across Multiple Protein Expression Cutoffs in Non-Small Cell Lung Cancer. Clin Cancer Res. 2017 Jul 15;23 (14):3585 – 3591.; Hendry S, Byrne DJ, Wright GM, Young RJ, et al. Comparison of Four PD-L1 Immunohistochemical Assays in Lung Cancer. J Thorac Oncol. 2018 Mar;13 (3):367 – 376.; Rimm DL, Han G, Taube JM, Yi ES et al. A prospective, multiinstitutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non-small cell lung cancer. JAMA Oncol. 2017;3:1051 – 1058.; Tsimafeyeu I, Imyanitov E, Zavalishina L, et al. Agreement between PDL1 immunohistochemistry assays and polymerase chain reaction in non-small cell lung cancer: CLOVER comparison study. Sci Rep. 2020;10 (1):3928. Published 2020 Mar 3. doi:10.1038/s41; https://www.malignanttumors.org/jour/article/view/697

Διαθεσιμότητα: https://www.malignanttumors.org/jour/article/view/697
https://doi.org/10.18027/2224-5057-2019-9-4-25-31

Cardiovascular complications of immune checkpoint inhibitors ; Сердечно-сосудистые осложнения терапии ингибиторами контрольных точек иммунитета

Συγγραφείς: A. A. Kulievа, E. I. Emelina, G. E. Gendlin, I. G. Nikitin, S. K. Zyryanov, S. I. Varentsov, I. I. Zakharova, А. А. Кулиева, Е. И. Емелина, Г. Е. Гендлин, И. Г. Никитин, С. К. Зырянов, С. И. Варенцов, И. И. Захарова

Πηγή: Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice; № 4 (2019); 55-65 ; Качественная клиническая практика; № 4 (2019); 55-65 ; 2618-8473 ; 2588-0519

Θεματικοί όροι: кардиоонкология, immune checkpoint inhibitors, myocarditis, cardio-oncology, ингибиторы контрольных точек иммунитета, миокардит

Περιγραφή αρχείου: application/pdf

Relation: https://www.clinvest.ru/jour/article/view/477/462; Cheng H, Force T. Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics. Circ Res. 2010;106(1):21— 34.; Moslehi JJ. Cardiovascular toxic effects of targeted cancer therapies. N Engl J Med. 2016;375(15):1457—1467.; Curigliano G, Cardinale D, Dent S, et al. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management. CA: A Cancer Journal for Clinicians. 2016;66(4):309—325. DOI:10.3322/caac.21341; Nelson MH, Paulos CM. Novel immunotherapies for hematologic malignancies. Immunol Rev. 2015 Jan;263(1):90-105. DOI:10.1111/imr.12245; Schadendorf D, van Akkooi ACJ, Berking C, et al. Melanoma. Lancet. 2018 Sep 15;392(10151):971-984. DOI:10.1016/S0140-6736(18)31559-9; Насонов Е.Л. Ингибиция иммунных контрольных точеки аутоиммунитет: ревматологические проблемы // Научно-практическая ревматология. — 2018. — Т.56. — № 1. — С.5-9. DOI:10.14412/19954484-2018-5-9; Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013;13:227-42. DOI:10.1038/nri3405; Jain V, Bahia J, Mohebtash M, Barac A. Cardiovascular complications associated with novel cancer immunotherapies. Curr Treat Options Cardiovasc Med. 2017 May;19(5):36. DOI:10.1007/s11936-017-0532-8; Atallah-Yunes SA, Kadado AJ, Kaufman GP, et al. Immune checkpoint inhibitor therapy and myocarditis: a systematic review of reported cases. J Cancer Res Clin Oncol. 2019;145:1527-1557. https://doi.org/10.1007/s00432019-02927-x; U.S. Department of Health and Human Services National Cancer Institute, Common terminology criteria for adverse events (CTCAE) version 5.0, https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm#ctc_50. Accessed date: 1 July 2019.; Norwood TG, Westbrook BC, Johnson DB, et al. Smoldering myocarditis following immune checkpoint blockade. J Immunother Cancer. 2017 Nov 21;5(1):91. DOI:10.1186/s40425-017-0296-4; Bajwa R, Cheema A, Khan T, et al. Adverse Effects of Immune Checkpoint Inhibitors (Programmed Death-1 Inhibitors and Cytotoxic T-LymphocyteAssociated Protein-4 Inhibitors): Results of a Retrospective Study. Journal of Clinical Medicine Research. 2019;11(4):225—236. DOI:10.14740/jocmr3750; Varricchi G, Galdiero MR, Marone G, et al. Cardiotoxicity of immune checkpoint inhibitors. ESMO Open. 2017;2:e000247. DOI:10.1136/esmoopen-2017-000247; Mahmood SS, Fradley MG, Cohen JV, et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol. 2018 Apr 24;71(16):1755-1764. DOI:10.1016/j.jacc.2018.02.037; Michel L, Rassaf T, Totzeck M. Cardiotoxicity from immune checkpoint inhibitors. Int J Cardiol Heart Vasc. 2019 Sep 7;25:100420. DOI:10.1016/j.ijcha.2019.100420; Ganatra S, Neilan TG. Immune checkpoint inhibitor associated myocarditis. Oncologist. 2018 Aug;23(8):879-886. DOI:10.1634/theoncologist.2018-0130; Frigeri M, Meyer P, Banfi C, et al. Immune checkpoint inhibitorassociated myocarditis: a new challenge for cardiologists. Can J Cardiol. 2018 Jan;34(1):92.e1-92.e3. DOI:10.1016/j.cjca.2017.09.025; Roth ME, Muluneh B, Jensen BC, et al. Left ventricular dysfunction after treatment with ipilimumab for metastatic melanoma. Am J Ther. 2016;23:e1925—8; Yun S, Vincelette ND, Mansour I, et al. Late onset ipilimumab induced pericarditis and pericardial effusion: a rare but life threatening complication. Case Rep Oncol Med. 2015;2015:1—5. DOI:10.1155/2015/794842; Lyon AR, Yousaf N, Battisti NML, Moslehi J, Larkin J. Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol. 2018 Sep;19(9):e447-e458. DOI:10.1016/S1470-2045(18)30457-1; Voskens CJ, Goldinger SM, Loquai C, et al. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One. 2013;8:e53745; Villadolid J, Amin A. Immune check point inhibitors in clinical practice: update on management of immunerelated toxicities. Transl Lung Cancer Res. 2015;4(5):560—75.; Jain V, Mohebtash M, Rodrigo ME, et al. Autoimmune myocarditis caused by immune checkpoint inhibitors treated with antithymocyte globulin. J Immunother. 2018 09;41(7):332-335.; Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 136.; Авксентьев Н.А., Фролов М.Ю., Макаров А.С. Фармакоэкономическое исследование применения пембролизумаба и ниволумаба во второй линии терапии распространённого немелкоклеточного рака лёгкого // Эффективная фармакотерапия. — 2019. — Т.15. — № 24. — С.38—46. DOI:10.33978/2307-3586-2019-15-24-38-46; https://www.clinvest.ru/jour/article/view/477

Διαθεσιμότητα: https://www.clinvest.ru/jour/article/view/477